Hyperbole, innuendo, and fact: The strange case of COX-2 selective inhibitors

Journal of Rheumatology

Volumn 33, Issue 1, 2006, Pages 1-3

  Simon, Lee S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ALZHEIMER DISEASE; ANALGESIA; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL RESEARCH; COLON POLYP; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG SAFETY; DRUG SELECTIVITY; EDEMA; EDITORIAL; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEALTH HAZARD; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RISK; THROMBOEMBOLISM; TREATMENT OUTCOME;

ARTHRITIS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS;

EID: 30144434969     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (30)

1. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57.
2. Lipsky PE, Abramson SB, Crofford L, Dubois RN, Simon L, van de Putte LBA. The classification of cyclooxygenase inhibitors [editorial]. J Rheumatol 1998;25:2298-303.
3. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
4. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LBA. Basic biology and clinical application of cyclooxygenase-2. Arthritis Rheum 2000;43:4-13.
5. Crofford LJ, Oates JC, McCune WI, et al. Thrombosis in patients with connective tissue disease treated with specific COX-2 inhibitors: a report of four cases. Arthritis Rheum 2000;43:1891-6.
6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
7. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000;160:913-20.
8. Lipsky PE, Abramson SB, Breedveld FC, et al. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000;27:1338-40.
9. Simon LS, Smolen JS, Abramson SB, et al. Controversies in COX-2 selective inhibition: Report from a consensus conference. J Rheumatol 2002;29;1501-10.
10. Wolfe CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51.
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
12. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 2000;284:1247-55.
13. Farkouh ME, Kirshner H, Harrington RA, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
14. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
15. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
16. Bresalier RS, Sandler RS, Quan H, et al, for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
17. Solomon SD, McMurray JJV, Pfeffer MA, et al, for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
18. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235-43.
19. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
20. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt induced hypertension. Circulation 2003;108:2308-11.
21. Sowers JR, White WB, Pitt B, et al, for the Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.
22. Erratum in Arch Intern Med 2005;165:551.
23. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12.
24. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
25. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
26. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
27. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
28. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? Ann Intern Med 1994;121:289-300.
29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary artery disease. Part 2: Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
30. Messerli FH, Sichrovsky T. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Am J Cardiol 2005;96:872-3.